T. Rowe Price Investment Management
DYN icon

T. Rowe Price Investment Management’s Dyne Therapeutics DYN Stock Holding History

T. Rowe Price Investment Management’s Portfolio DYN Stock Details DYN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$687M Buy
30,912,287
+126,486
+0.4% +$2.35M 0.45% 51
2026
Q1 		$558M Buy
30,785,801
+13,245,712
+76% +$228M 0.38% 69
2025
Q4 		$343M Buy
17,540,089
+14,727,667
+524% +$279M 0.22% 115
2025
Q3 		$35.6M Buy
2,812,422
+1,018,832
+57% +$11.6M 0.02% 427
2025
Q2 		$17.1M Buy
1,793,590
+625,615
+54% +$6.89M 0.01% 519
2025
Q1 		$12.2M Buy
+1,167,975
New +$16.7M 0.01% 550

Other funds holding DYN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $881M AUM 160.77% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

T. Rowe Price Investment Management's DYN Position: Q2 2026 in Review

T. Rowe Price Investment Management increased its Dyne Therapeutics (DYN) stake by 0.41% in Q2 2026, buying an estimated $2.35M and bringing the position to 30,912,287 shares worth $687M. The position accounts for 0.45% of the portfolio, ranked #51.

T. Rowe Price Investment Management first reported a position in DYN in Q1 2025 and has held it in 6 quarters since. 246 funds tracked by Wall St. Rank hold DYN as of Q2 2026.

  • T. Rowe Price Investment Management held 30,912,287 shares of Dyne Therapeutics worth $687M as of Q2 2026.
  • T. Rowe Price Investment Management bought 126,486 Dyne Therapeutics shares in Q2 2026, an estimated $2.35M.
  • Dyne Therapeutics made up 0.45% of T. Rowe Price Investment Management's portfolio in Q2 2026, its #51 holding.
  • T. Rowe Price Investment Management first reported a position in Dyne Therapeutics in Q1 2025 and has held it in 6 quarters since.
  • 246 funds tracked by Wall St. Rank held Dyne Therapeutics as of Q2 2026.

Based on T. Rowe Price Investment Management's 13F filing for Q2 2026, filed 14 Aug 2026.